CLEVELAND BIOLABS, INC. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. The Company's proprietary technology platform is based on the ability to suppress or stimulate programmed cell death (apoptosis). CBLI's drugs can switch apoptosis on and off by affecting key regulators of cell response to stresses, such as radiation or ischemia. CBLI is pursuing three key areas of research: Biodefense for Acute Radiation Syndrome, Cancer Treatment, and Tissue Protection. Cleveland Biolabs Inc. has a market cap of $59.7 million; its shares were traded at around $3.68 with and P/S ratio of 12.7.
Insiders' Positions with CBLI
- Sell:: CEO, President Michael Fonstein sold 5,000 shares of CBLI stock on 10/22/2009 at the average price of 4.19, the price of the stock has decreased by 12.17% since
- Sell:: CEO & President Michael Fonstein sold 5,000 shares of CBLI stock on 09/22/2009 at the average price of 3.87, the price of the stock has decreased by 4.91% since
- Sell:: CEO & President Michael Fonstein sold 5,000 shares of CBLI stock on 08/24/2009 at the average price of 4.27, the price of the stock has decreased by 13.82% since
Insiders' Positions with CBLI
- Sell:: Chief Scientific Officer Andrei V Gudkov sold 5,000 shares of CBLI stock on 11/16/2009 at the average price of 3.85, the price of the stock has decreased by 4.42% since
- Sell:: COO, Secretary Yakov Kogan sold 6,000 shares of CBLI stock on 11/02/2009 at the average price of 3.87, the price of the stock has decreased by 4.91% since
- Sell:: Chief Scientific Officer Andrei V Gudkov sold 5,000 shares of CBLI stock on 10/16/2009 at the average price of 4.76, the price of the stock has decreased by 22.69% since
- Sell:: COO, Secretary Yakov Kogan sold 6,000 shares of CBLI stock on 10/01/2009 at the average price of 4.11, the price of the stock has decreased by 10.46% since
- Sell:: Chief Scientific Officer Andrei V Gudkov sold 5,000 shares of CBLI stock on 09/16/2009 at the average price of 4.06, the price of the stock has decreased by 9.36% since
Become a Premium Member to See This: (Free Trial):
- CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
- Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
- Double Buys:: Companies that both Gurus and Insiders are buying
- Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.
Rate This Article: |
  |